复方芩兰口服液治疗急性上呼吸道感染的临床疗效观察  

Clinical observation of compound Qinlan oral liquid in treatment of acute upper respiratory tract infection

作　　者：郑雅丽 Zheng Yali(Community Health Service Center of Shilou Town,Fangshan District,Beijing City,Beijing 102422)

机构地区：[1]北京市房山区石楼镇社区卫生服务中心,北京102422

出　　处：《中国社区医师》2021年第27期103-104,共2页Chinese Community Doctors

摘　　要：目的:分析复方芩兰口服液治疗急性上呼吸道感染的临床疗效。方法:2019年5-10月收治急性上呼吸道感染患者200例,随机分为两组,各100例。试验组给予复方芩兰口服液治疗,对照组给予蒲地蓝消炎口服液治疗,比较两组临床疗效和安全性。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);试验组发热、咽喉肿痛、咳嗽及咯痰等症状好转时间均短于对照组,差异有统计学意义(P<0.05)。两组治疗期间均无不良事件发生。结论:复方芩兰口服液治疗急性上呼吸道感染,可获得更好的临床疗效,有效改善了临床症状及体征,且治疗期间未见严重不良反应,安全性有保障。Objective:To analyze the clinical effect of compound Qinlan oral liquid in the treatment of acute upper respiratory tract infection.Methods:From May 2019 to October 2019,200 patients with acute upper respiratory tract infection were selected and randomly divided into two groups with 100 cases in each group.The experimental group was treated with compound Qinlan oral liquid.The control group was treated with Pudilan anti-inflammatory oral solution.The clinical efficacy and safety between the two groups were compared.Results:The total effective rate of experimental group was higher than the control group,with the difference was statistically significant(P<0.05).The improvement time of fever,sore throat,cough and sputum in the experimental group was shorter than the control group,with the differences were statistically significant(P<0.05).No adverse events occurred during treatment in both groups.Conclusion:Compound Qinlan oral liquid can obtain better clinical efficacy in the treatment of patients with acute upper respiratory tract infection,effectively improve the clinical symptoms and signs,and no serious adverse reactions were observed during the treatment,and the safety is guaranteed.

关 键 词：复方芩兰口服液 急性上呼吸道感染 临床疗效 

分 类 号：R259[医药卫生—中西医结合]